undamentalytics Newsletter
Sign in

Voyager Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Voyager Therapeutics, Inc. had total assets of $252m, total liabilities of $56.2m and shareholders' equity of $196m. It held $65.3m in cash against $0 of debt: net cash of $65.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents31373247861041179969716536
Receivables————————80223
Total current assets196179172162305198137124320277203125
Total assets229190184177355262194159351393252198
Accounts payable111141132452
Deferred revenue (current)2073214783459432420
Total current liabilities241416327627517365502717
Total debt000000000000
Total liabilities60545013125510799100115935643
Shareholders' equity169136134461001549559236300196154
Net debt (negative = net cash)−31−37−32−47−86−104−117−99−69−71−65−36
Shares outstanding—26m32m32m37m37m38m39m44m55m59m61m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BHST vs VYGRCCCC vs VYGRFHTX vs VYGR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Voyager Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Voyager Therapeutics, Inc.